Smith T J, Somerfield M R
Massey Cancer Center, Virginia Commonwealth University, Richmond, USA.
Oncology (Williston Park). 1997 Nov;11(11A):223-7.
After strong demand from members, the American Society of Clinical Oncology (ASCO) began, in 1992, to formulate clinical practice guidelines. Guidelines were written for the following: outcomes from cancer treatment, hematopoietic colony-stimulating factors, tumor markers for breast and colorectal cancer, surveillance of breast cancer patients, and management of non-small-cell lung cancer. Further guidelines are being drafted for management of advanced prostate cancer, antiemetics, bisphosphonates in breast cancer and myeloma, chemoprotectants, and surveillance of colorectal cancer patients. This article explores the process by which ASCO guidelines are drafted, as well problems with these guidelines. Suggestions are made for ASCO and other professional groups that anticipate framing a set of guidelines.
应会员的强烈要求，美国临床肿瘤学会（ASCO）于1992年开始制定临床实践指南。这些指南涵盖以下方面：癌症治疗的结果、造血集落刺激因子、乳腺癌和结直肠癌的肿瘤标志物、乳腺癌患者的监测以及非小细胞肺癌的管理。目前正在起草关于晚期前列腺癌管理、止吐药、乳腺癌和骨髓瘤中的双膦酸盐、化学保护剂以及结直肠癌患者监测的进一步指南。本文探讨了ASCO指南的起草过程以及这些指南存在的问题。针对ASCO和其他预期制定一套指南的专业团体提出了建议。
